Comparisons of survival outcomes between bevacizumab and olaparib inBRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)

This publication has 28 references indexed in Scilit:

• Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
  The Lancet Oncology, 2017
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
  New England Journal of Medicine, 2016
• Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
  Gynecologic Oncology, 2015
• OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
  Journal of Clinical Oncology, 2012
• Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
  New England Journal of Medicine, 2012
• Clinical Trials in Recurrent Ovarian Cancer
  International Journal of Gynecological Cancer, 2011
• Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
  Annals of Oncology, 2011
• Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
  International Journal of Gynecological Cancer, 2011
• Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
  Cancer, 2009
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009